HuMax-CD32b™ is a fully human IgG1,k antibody targeting the CD32b receptor found on immune cells and hematological tumors.  HuMax-CD32b may have therapeutic potential in the treatment of B-cell chronic lymphocytic leukemia, small lymphocytic lymphoma, Burkitt's lymphoma, follicular and diffuse large B-cell lymphoma.

The lead candidate for HuMax-CD32b was selected from a panel of over 60 antibodies based on its excellent selectivity and binding ability for the CD32b target and potent triggering of the immune system killing mechanism antibody-dependent cellular cytotoxicity (ADCC).  The antibody was highly effective in suppressing tumor growth in vivo mouse tumor models in which tumor growth was monitored by highly sensitive bioluminescence imaging.

Pre-clinical Studies

 In animal models, HuMax-CD32b has been shown to induce impressive anti-tumor responses.  The CD32b receptor has an inhibitory role on immune cells and blockade of CD32b has been documented to strongly potentiate the therapeutic effects of other anti-tumor antibodies.  An antibody targeting CD32b may thus be attractive for combination therapy with other antibodies.